Thiazolidinedione inhibits production of RANTES in a cytokine-treated human lung epithelial cell line  by Momoi, Atsuko et al.
Thiazolidinedione inhibits production of RANTES in a cytokine-treated
human lung epithelial cell line
Atsuko Momoi, Koji Murao*, Hitomi Imachi, Yoshitaka Sayo, Hiroyuki Nakamura,
Hitoshi Hosokawa, Makoto Sato, Jiro Fujita, Hiroki Okada, Toshihiko Ishida, Jiro Takahara
First Department of Internal Medicine, Kagawa Medical University, 1750-1, Miki-cho, Kita-gun, Kagawa 761-0793, Japan
Received 4 March 1999; received in revised form 27 April 1999
Abstract The chemokine RANTES is a potent chemoattractant
for eosinophils. RANTES is produced by lung epithelial cells
during eosinophil-rich inflammatory diseases such as asthma. In
this study, we examined the effects of thiazolidinediones (TZD)
on RANTES expression in a human lung epithelial cell line,
A549. In A549 cells, interleukin-1L and tumor necrosis factor-K
induced endogenous RANTES protein secretion, mRNA expres-
sion, and promoter activity. The TZD inhibited these effects.
Our data indicate that the suppression of the expression of
RANTES can be accomplished by TZD treatment, raising the
possibility that TZD might be of therapeutic value in diseases
such as asthma.
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1. Introduction
Chemokines are a family of small molecular mass proteins
(8^16 kDa) that are originally classi¢ed based on the conser-
vation of a four-cysteine motif and on their ability to cause
the directed migration of leukocytes in vitro [1]. RANTES
(regulated upon activation normal T-cell expressed and se-
creted) is a member of a new class of chemokines [1,2] that
play an important role in allergic in£ammation. RANTES
exerts potent and selective chemoattractant e¡ects on cells
which characteristically predominate in the allergic in£amma-
tory cells, such as CD45RO memory T lymphocytes [3],
eosinophils [4], and mast cells [5]. In addition, RANTES is
produced by epithelial cells during eosinophil-rich in£amma-
tory diseases [6]. The bronchial asthma process is believed to
involve the activation of T helper 2-type lymphocytes with the
consequent accumulation of proin£ammatory e¡ector cells,
particularly eosinophils [7,8]. It is believed that RANTES
plays a signi¢cant role in the recruitment of eosinophils to
the bronchial mucosa.
Thiazolidinediones (TZD), which are known to have potent
enhancing e¡ects on insulin sensitivity, have been developed
for the treatment of non-insulin-dependent diabetes mellitus
[9]. TZD can speci¢cally and powerfully block the action of
tumor necrosis factor (TNF)-K to inhibit insulin signaling,
suggesting one plausible mechanism for its action in improv-
ing insulin resistance [10]. It has also been found that TZD
are a high-a⁄nity ligand for the peroxisome proliferator-acti-
vated receptor-Q (PPAR-Q), which belongs to a nuclear recep-
tor superfamily [11]. Two groups recently reported that
PPAR-Q activators such as 15-deoxy-v12;14 prostaglandin J2
(15d-PGJ2) and TZD can inhibit the production of several
in£ammatory cytokines including interleukin (IL)-1L and
TNF-K by phorbol 12-myristate 13-acetate and interferon-Q-
activated macrophages in vitro [12,13].
In this study, we examined the e¡ects of a TZD on expres-
sion of RANTES in response to IL-1L and TNF-K in human
lung epithelial cells. Our results demonstrate that the expres-
sion of RANTES was inhibited by the TZD at the transcrip-
tional level.
2. Materials and methods
2.1. Materials
The TZD was provided by Sankyo Pharmaceuticals (Tokyo, Ja-
pan). Wy14643 was from Cayman (Ann Arbor, MI, USA).
Dexamethasone (Dex) was from Wako Pure Chemical Industries
Ltd. (Osaka, Japan). TNF-K and IL-1L were obtained from Research
Biochemicals International (Natick, MA, USA). All other reagents
were of analytical grade.
2.2. Cell culture
A human lung adenocarcinoma cell line (A549 cells) representative
of distal respiratory epithelium was obtained from American Type
Culture Collection (Rockville, MD, USA). A549 cells were cultured
in RPMI 1640 media (Gibco BRL, Tokyo, Japan) supplemented with
10% heat-inactivated fetal bovine serum (Dainippon Pharmaceutical
Co., Tokyo, Japan), in a humidi¢ed atmosphere containing 5% CO2
at 37‡C. When con£uent, the cells were washed twice and incubated
with serum-free RPMI 1640 for 24 h before being stimulated with IL-
1L or TNF-K. One hour after cytokine stimulation, the cells were
treated with 10 WM TZD, 100 WM Wy14643 or 1 WM Dex for 24 h.
2.3. RNA isolation and Northern blot analysis
A single-step acid guanidinium thiocyanate-phenol-chloroform ex-
traction technique [14] was used to isolate total RNA from A549 cells
treated with cytokines and/or TZD for 24 h. The separation of the
RNA samples, transfer to membrane and hybridization with human
RANTES cDNA were described previously [15]. The 197 bp cDNA of
human RANTES was synthesized by a polymerase chain reaction
(PCR) method using reverse transcribed RNA as previous described
[15]. Primers used for PCR were as follows: sense: 5P-CGCT-
GTCATCCTCATTGCTA-3P, antisense: 5P-CACACACTTGGCG-
GTTCTT-3P. The probe used in the hybridization was radiolabeled
with [32P]dCTP (3000 Ci/mmol) using a random priming kit (TaKaRa
Biomedicals, Tokyo, Japan). The membranes were also stained with
methylene blue to assess the equal loading of samples [16]. After
autoradiography at room temperature for 24 h, hybridization signals
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were detected using a Bioimaging Analyzer (BAS 1000, Fuji Photo
Film, Tokyo, Japan).
2.4. Transfection of A549 cells and luciferase reporter gene assay
To con¢rm the transcriptional regulation by TZD of RANTES
expression, we used a promoter construct of the RANTES gene.
The reporter contains the human RANTES gene sequence spanning
the region from 31014 to +2 of the published sequence [17]; it was
ampli¢ed by PCR and cloned into the luciferase reporter gene
(pRANTES-LUC). Puri¢ed reporter plasmid was transfected into
A549 cells (at 60% con£uence) by conventional cationic liposome
transfection methods (Lipofectamine, Life Technologies, Gaithers-
burg, MD, USA). Two Wg of Rous sarcoma virus-L-galactosidase
was added to all transfections to monitor the e⁄ciency of DNA up-
take by A549 cells [18]. All assays were corrected for L-galactosidase
activity and total amounts of protein per reaction were identical.
Transfected cells were maintained in control media containing 1 ng/
ml IL-1L or 10 ng/ml TNF-K with or without TZD or Wy14643 for
24 h. Transfected cells were harvested, and an aliquot of the cytoplas-
mic fraction was taken for the measurement of L-galactosidase activ-
ity [18]. Aliquots of 20 Wl were taken for the luciferase assay, which
was performed according to the manufacturer’s instructions
(ToyoInk, Tokyo, Japan).
2.5. RANTES enzyme-linked immunosorbent assay (ELISA)
The levels of immunoreactive RANTES were quanti¢ed using a
commercially available sandwich-type ELISA (RpD Systems Inc.,
Minneapolis, MN, USA). This ELISA is sensitive to 2.5 pg/ml
RANTES, and it has an intra-assay coe⁄cient of variation of6 0.5%
and an interassay coe⁄cient of variation of 6 10%.
2.6. Chemotaxis assay
Eosinophils from allergic volunteers (peripheral blood eosinophil
count 5^10%) were separated on a discontinuous density Percoll col-
umn (American Pharmacia Biotech, Uppsala, Sweden). Eosinophil
chemotaxis experiments were performed using a 48 well chemotaxis
chamber as described previously [19]. The numbers of eosinophils that
migrated through the ¢lter were counted on ¢ve high-power ¢elds
(40U10) in duplicate. RPMI 1640 and human eotaxin (100 ng/ml)
were used as negative and positive controls, respectively.
2.7. Statistical analysis
Statistical comparisons were made by one-way analysis of variance
and Student’s t-test, with P6 0.05 considered signi¢cant.
3. Results
3.1. TZD block the IL-1L- and TNF-K-mediated stimulation of
RANTES secretion in A549 cells
Several studies have shown that IL-1L and TNF-K stimu-
late RANTES secretion and eosinophil accumulation by nor-
mal epithelial cells and A549 cells [20]. As expected, TNF-K
and IL-1L each stimulated the RANTES secretion in a dose-
dependent manner; the maximal e¡ect was observed at 10 ng/
ml TNF-K and 1 ng/ml IL-1L in A549 cells (data not shown).
This stimulation of RANTES secretion in human lung epithe-
lial cells was blocked by glucocorticoid [20,21]. We con¢rmed
that glucocorticoid inhibited the RANTES secretion by A549
cells treated with TNF-K or IL-1L (Fig. 1A,B). When cells
were pretreated with 10 WM TZD, it inhibited the RANTES
secretion by IL-1L-treated A549 cells at 8% compared to A549
cells treated only with IL-1L. TZD also inhibited RANTES
secretion by TNF-K-treated A549 cells. This inhibitory e¡ect
of TZD was dose-dependent. Doses of TZD as low as 10 nM
reduced the RANTES release in 24 h cultures stimulated with
1 ng/ml of IL-1L(data not shown). The concentration of TZD
giving half-maximal inhibition was approximately 0.5 WM. In
contrast, Wy14643, which is an agent acting through the re-
lated PPAR-K, had no activity to inhibit RANTES secretion
by cytokine-treated A549 cells.
3.2. E¡ect of TZD on eosinophil chemotaxis in A549 cells
TZD inhibition of RANTES secretion induced by IL-1L
and TNF-K in A549 cells was associated with decreased chem-
otactic activity. It has been reported that IL-1L and TNF-K
increase eosinophilic chemotactic activity in bronchial epithe-
lial cells and bronchial cell lines [20,21]. Fig. 2 shows that IL-
1L and TNF-K stimulated the eosinophilic chemotactic activ-
ity in A549 cells. This increase in eosinophilic chemotactic
activity was inhibited by TZD in A549 cells, indicating that
the inhibition of RANTES secretion of both TZD- and cyto-
kine-treated A549 cells re£ected the eosinophilic chemotactic
activity in A549 cells.
3.3. E¡ect of TZD on RANTES mRNA in A549 cells
Using a human RANTES-speci¢c probe, we performed
Northern blot analyses, and detected a signal transcript of
1.2 kb, as previously reported [22]. As shown in Fig. 3,
both IL-1L and TNF-K stimulated the expression of
RANTES in A549 cells, in agreement with previous reports
[20,21]. TZD suppressed the induction of the RANTES
mRNA in A549 cells treated with IL-1L but not TNF-K. In
contrast, TZD had no e¡ects on the steady-state expression of
Fig. 1. Inhibition of cytokine-induced RANTES protein secretion
by TZD in A549 cells. E¡ects of TZD, Wy14643, and Dex on the
induction of RANTES by IL-1L (A) and TNF-K (B). A549 cells
were co-incubated with either 1 WM Dex, 10 WM TZD or 100 WM
Wy14643 in medium containing 1 ng/ml IL-1L or 10 ng/ml TNF-K.
RANTES release into the medium was measured by an ELISA. The
asterisk denotes a signi¢cant di¡erence (P6 0.05); N.S., no signi¢-
cant di¡erence. Error bars show S.E.M. of three determinations.
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RANTES in the cells. It had no e¡ect on cell viability, as
determined by the cell number and cell morphology (data
not shown).
3.4. E¡ects of TZD on human RANTES promoter in A549
cells treated with IL-1L
The response of pRANTES-LUC to 1 ng/ml of IL-1L in
A549 cells is shown in Fig. 4A. Consistent with the observed
changes in the level of endogenous RANTES mRNA, 1 ng/ml
IL-1L stimulated promoter activity. In the presence of both
IL-1L and TZD, TZD inhibited the IL-1L-induced RANTES
promoter activity in A549 cells. In contrast, TZD had no
e¡ect of the TNF-K-induced RANTES promoter activity in
A549 cells (Fig. 4B). These ¢ndings indicate that the activity
of the human RANTES promoter in A549 cells following
exposure to IL-1L and TZD re£ected the endogenous expres-
sion of RANTES mRNA.
4. Discussion
In this study, we examined the e¡ects of TZD on RANTES
expression in response to cytokines in a human lung cell line,
A549. Interest in this topic stems from the clinical observation
that eosinophils accumulate in patients with asthma [7,8].
RANTES is known to directly stimulate eosinophil migration
and to up-regulate the expression of the adhesion molecule
Mac-1 on eosinophils [23]. A clinical study showed that
RANTES is a major eosinophil chemoattractant in the bron-
choalveolar lavage £uid of asthmatic subjects [24].
When A549 cells were exposed to the cytokines IL-1L or
TNF-K, the cytokines stimulated not only RANTES mRNA
expression and protein secretion but also RANTES promoter
activity. Previous studies showed that TNF-K and IL-1L in-
crease the RANTES mRNA expression and release [20,21].
TNF-K or other cytokines released by alveolar macrophages
Fig. 2. Eosinophil chemotactic activity in supernatant of A549 cells.
Culture medium alone was used as a negative control and eotaxin
(100 ng/ml) was used as a positive control. Supernatants were ob-
tained from 24 h cultured cells in the presence of TNF-K or IL-1L
with/without 10 WM TZD. S.E.M. of three or four separate experi-
ments is shown. 1, medium; 2, eotaxin; 3, control; 4, IL-1L ; 5, IL-
1L+TZD; 6, TNF-K ; 7, TNF-K+TZD. HPF: high-power ¢eld. The
asterisk and double asterisk denote signi¢cant di¡erences (P6 0.01
and P6 0.05, respectively).
Fig. 3. TZD inhibits RANTES mRNA expression in cytokine-
treated A549 cells. 10 Wg of total RNA isolated from A549 cells
treated for 24 h with 1 ng/ml IL-1L or 10 ng/ml TNF-K with/with-
out 10 WM TZD was separated by agarose gel electrophoresis and
transferred to a membrane. The blots were hybridized with the cod-
ing region of human RANTES [32P]cDNA (A) and methylene blue
staining of 28S and 18S ribosomal RNA, demonstrating the similar-
ity of the quantity of RNA in each lane (B). Lane 1, control; lane
2, IL-1L ; lane 3, IL-1L+TZD; lane 4, TNF-K ; lane 5, TNF-
K+TZD. An identical experiment independently performed gave
similar results.
Fig. 4. E¡ect of TZD on RANTES promoter activity in A549 cells.
A549 cells were transfected with 10 Wg of pRANTES-LUC and
treated with 1 ng/ml IL-1L (A) or 10 ng/ml TNF-K (B) and/or
10 WM TZD, 100 WM Wy14643 for 24 h prior to cell harvest. All
assays were corrected for L-galactosidase activity and total amounts
of protein per reaction were identical. The results are expressed as
relative luciferase activities compared to control cells arbitrarily set
at 100. Each data point shows the mean and S.E.M. (n = 4) of sepa-
rate transfections. The asterisk denotes a signi¢cant di¡erence
(P6 0.01); N.S., no signi¢cant di¡erence.
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may stimulate lung epithelial cells to release RANTES, which
in turn recruits eosinophils together with T lymphocytes and
monocytes into the lung [1]. In this study, TZD inhibited not
only the IL-1L-induced RANTES mRNA expression and pro-
tein secretion but also RANTES promoter activity. TZD also
inhibited the TNF-K-induced RANTES secretion but not the
transcription of the RANTES gene. The reason for this dis-
crepancy between RANTES secretion and transcription in
response to TZD in TNF-K-treated A549 cells is unknown.
Although the exact mechanism of the cytokine-mediated in-
duction of RANTES expression is unknown, our present re-
sults indicate that the inhibition of cytokine-mediated
RANTES expression by TZD was partially regulated at the
transcriptional level. The answer to these questions will be
clari¢ed when the precise mechanism by which TNF-K and
IL-1L stimulate RANTES expression in lung epithelial cells is
known. Not only RANTES but also several factors such as
eotaxin and granulocyte/macrophage colony-stimulating fac-
tor have previously been shown to have chemotactic activity
for eosinophils and to be expressed in human bronchial epi-
thelial cells [25], and therefore the e¡ect of TZD on expression
of these factors deserves further investigations.
The 5P-£anking region of the RANTES gene contains a
large number of potential binding sites for transcriptional
factors [26]. PPAR-Q, which is one of the transcriptional fac-
tors, is thought to be the functional receptor for the TZD
[11,27]. A previous report indicated that 15d-PGJ2 and
PPAR-Q ligand inhibit STAT, NF-UB and AP-1 activity in a
PPAR-Q-dependent manner [12]. PPAR-Q is expressed at high-
est levels in adipose tissue, although it is also expressed in
other tissues at much lower levels. We have found that
PPAR-Q mRNA was expressed at a considerable level in
A549 cells by a reverse transcription-PCR method (data not
shown). We analyzed the promoter region of the RANTES
gene [26] and identi¢ed a sequence (3638 to 3625) with ho-
mology to the PPAR-Q consensus sequence. The DNA motif
in RANTES shares 84% homology with a similar PPAR-Q
consensus sequence found in the CD36 promoter sequence
[28]. Although the precise mechanism underlying the inhibi-
tion of the cytokine-induced RANTES expression by TZD is
unknown, the activation of PPAR-Q by a TZD may modulate
the activation of several transcriptional factors in response to
cytokines. Further examinations are necessary to determine
the transcriptional regulation of the RANTES gene by TZD
and cytokines.
Glucocorticoids are potent agents for the treatment of asth-
ma, but the clinical use of glucocorticoids for asthma is lim-
ited by their severe side e¡ects. Our results indicate that TZD
inhibits RANTES. Therefore, TZD might be useful drugs for
the treatment of asthmatic patients. Understanding the path-
ways leading to the activation of TZD might expose new
targets for the development of disease-modifying antiasth-
matic drugs; however, this hypothesis requires further exami-
nations using normal bronchial epithelial cells.
In summary, we examined the e¡ects of TZD on RANTES
expression in response to IL-1L and TNF-K in human lung
epithelial cells. The results indicate that the suppression of
RANTES expression can be accompanied by TZD treatment,
raising the possibility that TZD may have therapeutic value in
human diseases such as asthma in which RANTES plays an
important role.
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